Social integration processes in Estonia and Slovakia

Studies of interethnic integration in Central Eastern Europe have sought to account for the impact that institutional settings, structural conditions and elite-level interaction have on the accommodation of and conflict resolution between ethnic groups. Much existing literature has placed particular emphasis on the importance of institutional factors, both domestically and as a result of international pressure. Simultaneously, scholarship on the issue has left out of focus the contributions of non-dominant minority actors to the dynamics of interethnic relations. Where minorities are taken into account, this happens largely in terms of their failure to recognise structural opportunities for their inclusion into majority society. This study analyses interethnic integration in the Central Eastern European context from the perspective of structuration theory. Structuration theory provides a sound theoretical foundation in order to study non-dominant agency and its impact on the structures of integration, owing to its ability to reconcile dichotomies. The thesis comprises a comparative case study of interethnic interaction in Estonia and Slovakia, focusing on the Russian-speaking and the Hungarian minority respectively. A structuration approach is applied to the empirical findings in order to problematise practices of integration and their constraints that lie in the institutional and interaction context of Estonian and Slovak post-Communist society. I argue that although Russian-speakers in Estonia and Hungarians in Slovakia are constrained by institutional environs and majority-dominated structures, minority members actively participate in and shape institution-building and group formation in their interaction with majorities. Minority integration is analysed in terms of the minorities’ co-operation within, counteraction against and formulation of alternatives to the status quo structures of interethnic relations

Philipp Greters Landtaffel der schönen Gelegenheit und Landschaft umb Boll anno 1602

PHILIPP GRETERS LANDTAFFEL DER SCHÖNEN GELEGENHEIT UND LANDSCHAFT UMB BOLL ANNO 1602 Philipp Greters Landtaffel der schönen Gelegenheit und Landschaft umb Boll anno 1602 (-) Einband (-) Titelseite (-) Vorwort ([3]) Einleitung ([5]) Die Landtaffel der schönen Gelegenheit und Landschaft umb Boll vom Jahre 1602. Ein Kartenjubiläum. (7) Landtaffel der schönen Gelegenheit und Landschaft umb Boll / Anno 1602. ([10-11]) Die Ortsnamen der Boller Landtafel. / Zum Teil erläutert durch die Textworte des zugehörigen Bauhin-Förterßchen Neuen Boller Badbuchs. Stuttgart 1602. (13) Die Bergformen der Boller Landtafel. (14) Die Landtafeln des Herzogtums Württemberg im ehemaligen Lusthaus zu Stuttgart. / Gemalt in den Jahren 1590 - 1592. (15) Landtaffel der schönen Gelegenheit und Landschafft umb Boll / Anno 1602. (-) Einband (-

Compartmentalization of Cells Bearing "Rheumatic” Cell Surface Antigens in Peripheral Blood and Tonsils in Rheumatic Heart Disease

Monoclonal antibodies that recognize "rheumatic” antigens of peripheral blood non-T cells were used to study the compartmentalization of such cells in peripheral blood and tonsils of individuals with rheumatic heart disease (RHD) and suitable control subjects. The peripheral blood of most (71%) of the 42 individuals with RHD contained cells reacting with monoclonal antibody 83S19.23 or 256S.10, whereas these cells were present in only 17% of the 41 control subjects (P < .02). However, none of 21 individuals with RHD had such cells in their tonsils, although they were present in the tonsils of 50% of the 40 control subjects (P < .03). These results may reflect a failure in RHD of organ-specific homing of cells with the epitopes recognized by the antibodies. The presence of these cells in tonsils may be important in the immune response to streptococcal pharyngeal infection, and their absence in RHD may be involved in the unusual immune responses characteristic of this diseas

An open-label extension study of ivacaftor in children with CF and a CFTR gating mutation initiating treatment at age 2-5 years (KLIMB).

BACKGROUND: KIWI (NCT01705145) was a 24-week, single-arm, pharmacokinetics, safety, and efficacy study of ivacaftor in children aged 2 to 5 years with cystic fibrosis (CF) and a CFTR gating mutation. Here, we report the results of KLIMB (NCT01946412), an 84-week, open-label extension of KIWI. METHODS: Children received age- and weight-based ivacaftor dosages for 84 weeks. The primary outcome was safety. Other outcomes included sweat chloride, growth parameters, and measures of pancreatic function. RESULTS: All 33 children who completed KIWI enrolled in KLIMB; 28 completed 84 weeks of treatment. Most adverse events were consistent with those reported during KIWI. Ten (30%) children had transaminase elevations >3 × upper limit of normal (ULN), leading to 1 discontinuation in a child with alanine aminotransferase >8 × ULN. Improvements in sweat chloride, weight, and body mass index z scores and fecal elastase-1 observed during KIWI were maintained during KLIMB; there was no further improvement in these parameters. CONCLUSIONS: Ivacaftor was generally well tolerated for up to 108 weeks in children aged 2 to 5 years with CF and a gating mutation, with safety consistent with the KIWI study. Improvements in sweat chloride and growth parameters during the initial 24 weeks of treatment were maintained for up to an additional 84 weeks of treatment. Prevalence of raised transaminases remained stable and did not increase with duration of exposure during the open-label extension

The evolutionary rewiring of ubiquitination targets has reprogrammed the regulation of carbon assimilation in the pathogenic yeast Candida albicans

Date of Acceptance: 13/11/2012 This is an open-access article distributed under the terms of the Creative Commons Attribution-Noncommercial-ShareAlike 3.0 Unported license, which permits unrestricted noncommercial use, distribution, and reproduction in any medium, provided the original author and source are credited. Correction for Sandai et al., The Evolutionary Rewiring of Ubiquitination Targets Has Reprogrammed the Regulation of Carbon Assimilation in the Pathogenic Yeast Candida albicans published 20-01-2015 DOI: 10.1128/mBio.02489-14Peer reviewedPublisher PD

Assessing time to pulmonary function benefit following antibiotic treatment of acute cystic fibrosis exacerbations

<p>Abstract</p> <p>Background</p> <p>Cystic Fibrosis (CF) is a life-shortening genetic disease in which ~80% of deaths result from loss of lung function linked to inflammation due to chronic bacterial infection (principally <it>Pseudomonas aeruginosa</it>). Pulmonary exacerbations (intermittent episodes during which symptoms of lung infection increase and lung function decreases) can cause substantial resource utilization, morbidity, and irreversible loss of lung function. Intravenous antibiotic treatment to reduce exacerbation symptoms is standard management practice. However, no prospective studies have identified an optimal antibiotic treatment duration and this lack of objective data has been identified as an area of concern and interest.</p> <p>Methods</p> <p>We have retrospectively analyzed pulmonary function response data (as forced expiratory volume in one second; FEV₁) from a previous blinded controlled CF exacerbation management study of intravenous ceftazidime/tobramycin and meropenem/tobramycin in which spirometry was conducted daily to assess the time course of pulmonary function response.</p> <p>Results</p> <p>Ninety-five patients in the study received antibiotics for at least 4 days and were included in our analyses. Patients received antibiotics for an average of 12.6 days (median = 13, SD = 3.2 days), with a range of 4 to 27 days. No significant differences were observed in mean or median treatment durations as functions of either treatment group or baseline lung disease stage. Average time from initiation of antibiotic treatment to highest observed FEV₁was 8.7 days (median = 10, SD = 4.0 days), with a range of zero to 19 days. Patients were treated an average of 3.9 days beyond the day of peak FEV₁(median = 3, SD = 3.8 days), with 89 patients (93.7%) experiencing their peak FEV₁improvement within 13 days. There were no differences in mean or median times to peak FEV₁as a function of treatment group, although the magnitude of FEV₁improvement differed between groups.</p> <p>Conclusions</p> <p>Our results suggest that antibiotic response to exacerbation as assessed by pulmonary function is essentially complete within 2 weeks of treatment initiation and relatively independent of the magnitude of pulmonary function response observed.</p

Acute respiratory infection in patients with cystic fibrosis with mild pulmonary impairment: Comparison of two physiotherapy regimens

Chest physiotherapy is an essential part of the management of cystic fibrosis, yet comparatively few studies have investigated the commonly used forms of chest physiotherapy during acute respiratory exacerbations. Fifteen subjects with cystic fibrosis and predominantly mild pulmonary impairment completed a randomised cross-over trial with 24 hours between treatments. The active cycle of breathing techniques (ACBT) assisted by a physiotherapist was compared with the ACBT performed independently by the patient. Measurement outcomes included pulmonary function tests, indirect calorimetry and oximetry parameters. Energy expenditure was not significantly different between the two treatment regimens, though significant improvements in pulmonary function were apparent 24 hours following the therapist-assisted ACBT. In this group of subjects, neither form of treatment proved superior in terms of energy consumption, but a reduction in airways obstruction was observed as a carry-over effect following the therapist-assisted ACBT.Marie T Williams, David W Parsons , Ross A Frick, Elizabeth R Ellis, A James Martin, Sally E Giles and E Ruth Gran